NEEDHAM, Mass.--(BUSINESS WIRE)--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN) today announced that the Defense Appropriations Bill for Fiscal Year 2007 passed by Congress last week provides $2.6 million for the Defense Department’s continued development of an oral combination vaccine to protect against anthrax and plague, a project being carried out by AVANT. The dedicated funding supports continued development of this advanced technology vaccine begun by AVANT in January 2003. This financial support will help fund the research and clinical development phase of this combination vaccine, being carried out at AVANT’s research facility in Overland, Missouri, as well as vaccine production at AVANT’s Fall River, Massachusetts facility.
